These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37990165)

  • 1. A circulating vaccine-derived poliovirus type 2 outbreak in a chronic conflict setting: a descriptive epidemiological study in South Sudan - 2020 to 2021.
    Tegegne AA; Anyuon AN; Legge GA; Ferede MA; Isaac Z; Laku KA; Biadgilign S; Kilo OTD; Ndenzako F; Modjirom N; Olu OO; Maleghemi S
    BMC Infect Dis; 2023 Nov; 23(1):816. PubMed ID: 37990165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute flaccid paralysis surveillance performance from 2011 to 2020 in Jonglei State, South Sudan: progress and challenges encountered.
    Jil JM; Tegegne AA; Maleghemi S; Berta KK; Birru TG; Kilo OTD
    Pan Afr Med J; 2022; 42(Suppl 1):11. PubMed ID: 36158927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
    Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epidemiological analysis of Acute Flaccid Paralysis (AFP) surveillance in Kenya, 2016 to 2018.
    Tesfaye B; Sowe A; Kisangau N; Ogange J; Ntoburi S; Nekar I; Muitherero C; Camara Y; Gathenji C; Langat D; Sergon K; Limo H; Nzunza R; Kiptoon S; Kareko D; Onuekwusi I
    BMC Infect Dis; 2020 Aug; 20(1):611. PubMed ID: 32811467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polio eradication in a chronic conflict setting lessons from the Republic of South Sudan, 2010-2020.
    Maleghemi S; Tegegne AA; Ferede M; Bassey BE; Akpan GU; Bello IM; Ticha JM; Anyuon A; Waya JL; Okiror SO; Ndoutabe M; Berta KK; Ndenzako F; Mkanda P; Olu OO
    Pan Afr Med J; 2022; 42(Suppl 1):3. PubMed ID: 36158939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping a polio outbreak in the midst of war: Lessons from Syria.
    Mbaeyi C; Moran T; Wadood Z; Ather F; Sykes E; Nikulin J; Al Safadi M; Stehling-Ariza T; Zomahoun L; Ismaili A; Abourshaid N; Asghar H; Korukluoglu G; Duizer E; Ehrhardt D; Burns CC; Sharaf M
    Vaccine; 2021 Jun; 39(28):3717-3723. PubMed ID: 34053791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.
    Al-Qassimi MA; Al Amad M; Al-Dar A; Al Sakaf E; Al Hadad A; Raja'a YA
    BMC Infect Dis; 2024 Mar; 24(1):321. PubMed ID: 38491425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sensitivity of acute flaccid paralysis surveillance - the case of South Sudan: retrospective secondary analysis of AFP surveillance data 2014-2019.
    Tegegne AA; Maleghemi S; Anyuon AN; Zeleke FA; Legge GA; Ferede MA; Manyanga PD; Paul VG; Mutebi NM; Ticha JM; Kilo OTD; Ndenzako F; Pascal M; Olu OO
    Pan Afr Med J; 2022; 42(Suppl 1):12. PubMed ID: 36158926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Morais A; Morais J; Felix M; Neto Z; Madaleno V; Umar AS; Panda N; Lemma F; Chivale JAL; Cavalcante DG; Davlantes E; Ghiselli M; Espinosa C; Whiteman A; Iber J; Henderson E; Bullard K; Jorba J; Burns CC; Diop O; Gumede N; Seakamela L; Howard W; Frawley A
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A48-A57. PubMed ID: 36803869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
    Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
    Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study.
    Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM
    Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
    Darwar R; Biya O; Greene SA; Jorba J; Al Safadi M; Franka R; Wiesen E; Durry E; Pallansch MA
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A25-A34. PubMed ID: 36863925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
    Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
    Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020.
    Macklin GR; Goel AK; Mach O; Tallis G; Ahmed JA; O'Reilly KM; Grassly NC; Diop OM
    Vaccine; 2023 Apr; 41 Suppl 1():A19-A24. PubMed ID: 36008232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of wild polio virus outbreak investigation and response in Ethiopia in 2013-2014: implications for prevention of outbreaks due to importations.
    Tegegne AA; Braka F; Shebeshi ME; Aregay AK; Beyene B; Mersha AM; Ademe M; Muhyadin A; Jima D; Wyessa AB
    BMC Infect Dis; 2018 Jan; 18(1):9. PubMed ID: 29304745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak.
    Kidanne L; Bisrat F; Mohammed M; Deyessa N
    Pan Afr Med J; 2022; 42():46. PubMed ID: 35949467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.
    Voorman A; Lyons H; Shuaib F; Adamu US; Korir C; Erbeto T; Bandyopadhyay AS; Okiror S
    J Infect Dis; 2024 Mar; 229(3):805-812. PubMed ID: 37357964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.